Advertisement
A vs CRL
Which Stock Would AI Choose? Agilent Technologies (A) vs. Charles River Laboratories International (CRL) Stock Comparison
Key Takeaways
- Both A and CRL operate in the diagnostics and research segment of the healthcare sector, providing tools and services that support pharmaceutical and biotechnology development.
- In recent market activity, A has shown relative resilience with a smaller year-to-date decline compared to broader sector pressures, while CRL posted a first-quarter earnings beat that supported modest price recovery.
- A benefits from diversified exposure across life sciences, diagnostics, and applied markets, whereas CRL focuses more narrowly on contract research and early-stage drug development services.
- Market sentiment for CRL has been influenced by steady demand for its services following recent earnings, while A awaits its second-quarter results scheduled for late May.
- Risk factors for both include sensitivity to biopharma spending cycles and broader economic conditions affecting research budgets.
- Relative performance highlights trade-offs between A's broader platform stability and CRL's specialized service model with recent positive catalysts.
Introduction
Agilent Technologies (A) and Charles River Laboratories International (CRL) represent two distinct but related plays within the healthcare diagnostics and research space. Investors and traders seeking exposure to life sciences tools, drug discovery services, and biopharma support may find this comparison useful for assessing relative positioning. The analysis examines business models, recent performance trends, and market dynamics to provide a factual basis for evaluating these stocks in the current environment.
Agilent Technologies (A) Overview and Recent Performance
Agilent Technologies develops and manufactures analytical instruments, reagents, and software used in life sciences, diagnostics, and applied chemical markets. In recent weeks, the stock has traded in a range reflecting mixed sector sentiment, with year-to-date declines tempered by signs of stabilizing demand in its clinical and biopharma segments. Recent market activity has been shaped by order growth trends and anticipation of second-quarter fiscal 2026 results, scheduled for release on May 27. Broader macroeconomic factors influencing research spending have contributed to price behavior, resulting in a performance profile that has held up better than some peers on a year-to-date basis.
Charles River Laboratories International (CRL) Overview and Recent Performance
Charles River Laboratories International provides contract research, development, and manufacturing services focused on early-stage drug discovery and safety testing. Recent market activity has featured a first-quarter earnings report that exceeded consensus expectations, driven by steady demand for its services. The stock has shown modest recovery following that release amid ongoing biopharma client activity. Over the past month, price movements have reflected sector volatility, with the company maintaining its positioning as a key partner for pharmaceutical and biotechnology firms navigating development pipelines.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of AI trading bots optimized for prevailing market conditions. While Tickeron offers hundreds of AI Trading Bots capable of trading thousands of different tickers, only those demonstrating strong suitability based on current trends, strategies, and performance metrics are featured in this section. Available bots span a wide range of trading styles, timeframes, risk parameters, and historical statistics, with many reporting win rates between 55% and 75% alongside varying profit factors and drawdown profiles across diverse ticker sets. This variety allows users to explore options aligned with specific objectives. For more details, visit Trending AI Robots.
Head-to-Head Comparison
Agilent Technologies operates a diversified instrumentation and consumables business across multiple end markets, providing broader exposure to life sciences research and diagnostics compared with Charles River Laboratories International’s specialized focus on contract research organization (CRO) services for early-stage drug development. Growth drivers for A include recurring revenue from reagents and software, while CRL relies on client project pipelines in biopharma. Recent momentum has favored CRL following its earnings beat, whereas A has demonstrated relative stability amid upcoming results. Risk factors for both include cyclical biopharma spending, though A’s hardware and consumables mix may offer different sensitivity than CRL’s service-oriented model. Sector exposure remains aligned in healthcare diagnostics and research, with market sentiment influenced by overall industry funding trends and individual company catalysts.
Tickeron AI Verdict
Based on observable factors such as recent earnings consistency and positioning relative to sector trends, Tickeron’s AI would currently assign a modestly higher probability of favorable near-term momentum to CRL due to its earnings beat and service demand signals, while noting A’s upcoming results as a key variable that could alter relative positioning. This assessment reflects probabilistic evaluation of trend stability and catalysts rather than definitive outcomes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a Hold and CRL is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 1 FA rating(s) are green whileCRL’s FA Score has 1 green FA rating(s).
- A’s FA Score: 1 green, 4 red.
- CRL’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 5 TA indicator(s) are bullish while CRL’s TA Score has 7 bullish TA indicator(s).
- A’s TA Score: 5 bullish, 5 bearish.
- CRL’s TA Score: 7 bullish, 3 bearish.
Price Growth
A (@Medical Specialties) experienced а -3.14% price change this week, while CRL (@Medical Specialties) price change was -3.67% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +1.04%. For the same industry, the average monthly price growth was +3.10%, and the average quarterly price growth was -2.79%.
Reported Earning Dates
A is expected to report earnings on Aug 18, 2026.
CRL is expected to report earnings on Aug 12, 2026.
Industries' Descriptions
@Medical Specialties (+1.04% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| A | CRL | A / CRL | |
| Capitalization | 35.7B | 8.75B | 408% |
| EBITDA | 1.96B | 291M | 674% |
| Gain YTD | -6.662 | -8.983 | 74% |
| P/E Ratio | 25.40 | 577.05 | 4% |
| Revenue | 7.23B | 4.03B | 180% |
| Total Cash | 1.81B | 192M | 941% |
| Total Debt | 3.36B | 3.06B | 110% |
A | CRL | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 91 | 85 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | 88 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 44 | 94 | |
PRICE GROWTH RATING 1..100 | 47 | 43 | |
P/E GROWTH RATING 1..100 | 62 | 1 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (6) in the Biotechnology industry is significantly better than the same rating for CRL (88) in the Miscellaneous Commercial Services industry. This means that A’s stock grew significantly faster than CRL’s over the last 12 months.
A's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CRL (100) in the Miscellaneous Commercial Services industry. This means that A’s stock grew similarly to CRL’s over the last 12 months.
A's SMR Rating (44) in the Biotechnology industry is somewhat better than the same rating for CRL (94) in the Miscellaneous Commercial Services industry. This means that A’s stock grew somewhat faster than CRL’s over the last 12 months.
CRL's Price Growth Rating (43) in the Miscellaneous Commercial Services industry is in the same range as A (47) in the Biotechnology industry. This means that CRL’s stock grew similarly to A’s over the last 12 months.
CRL's P/E Growth Rating (1) in the Miscellaneous Commercial Services industry is somewhat better than the same rating for A (62) in the Biotechnology industry. This means that CRL’s stock grew somewhat faster than A’s over the last 12 months.
| A | CRL | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 76% | 2 days ago 74% |
| Stochastic ODDS (%) | 2 days ago 56% | 2 days ago 70% |
| Momentum ODDS (%) | 2 days ago 60% | 2 days ago 72% |
| MACD ODDS (%) | 2 days ago 59% | 2 days ago 72% |
| TrendWeek ODDS (%) | 2 days ago 64% | 2 days ago 74% |
| TrendMonth ODDS (%) | 2 days ago 58% | 2 days ago 65% |
| Advances ODDS (%) | 9 days ago 60% | 15 days ago 69% |
| Declines ODDS (%) | 7 days ago 62% | 7 days ago 71% |
| BollingerBands ODDS (%) | 2 days ago 52% | 2 days ago 75% |
| Aroon ODDS (%) | 2 days ago 67% | 2 days ago 65% |
Advertisement
A and
Correlation & Price change
A.I.dvisor indicates that over the last year, A has been closely correlated with TMO. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if A jumps, then TMO could also see price increases.
CRL and
Correlation & Price change
A.I.dvisor indicates that over the last year, CRL has been closely correlated with IQV. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRL jumps, then IQV could also see price increases.